Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

Francesco Marampon, Flavio Leoni, Andrea Mancini, Ilaria Pietrantoni, Silvia Codenotti, Ferella Letizia, Francesca Megiorni, Giuliana Porro, Elisabetta Galbiati, Pietro Pozzi, Paolo Mascagni, Alfredo Budillon, Roberto Maggio, Vincenzo Tombolini, Alessandro Fanzani, Giovanni Luca Gravina, Claudio Festuccia

Research output: Contribution to journalArticle

Abstract

PURPOSE: Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential.

METHODS: A set of GBM- and patient-derived GBM stem-cell lines was used and the ITF2357 effects on GBM oncophenotype were investigated in in vitro and in vivo xenograft models.

RESULTS: ITF2357 inhibited HDAC activity and affected GBM cellular fate in a dose-dependent manner by inducing G1/S growth arrest (1-2.5 µM) or caspase-mediated cell death (≥ 2.5 µM). Chronic treatment with low doses (≤ 1 µM) induced autophagy-mediated cell death, neuronal-like phenotype, and the expression of differentiation markers, such as glial fibrillar actin protein (GFAP) and neuron-specific class III beta-tubulin (Tuj-1); this reduces neurosphere formation from patient-derived GBM stem cells. Autophagy inhibition counteracted the ITF2357-induced expression of differentiation markers in p53-expressing GBM cells. Finally, in in vivo experiments, ITF2357 efficiently passed the blood-brain barrier, so rapidly reaching high concentration in the brain tissues, and significantly affected U87MG and U251MG growth in orthotopic xenotransplanted mice.

CONCLUSIONS: The present findings provide evidence of the key role played by HDACs in sustaining transformed and stem phenotype of GBM and strongly suggest that ITF2357 may have a clinical potential for the HDACi-based therapeutic strategies against GBM.

Original languageEnglish
Pages (from-to)393-409
Number of pages17
JournalJournal of Cancer Research and Clinical Oncology
Volume145
Issue number2
DOIs
Publication statusPublished - Feb 2019

Fingerprint

Histone Deacetylase Inhibitors
Glioblastoma
Phenotype
Histone Deacetylases
Differentiation Antigens
Autophagy
Cell Death
Stem Cells
In Vitro Techniques
givinostat hydrochloride
givinostat
Tubulin
Growth
Caspases
Blood-Brain Barrier
Heterografts
Neuroglia
Actins
Neurons
Cell Line

Keywords

  • Animals
  • Apoptosis
  • Carbamates/pharmacology
  • Cell Movement
  • Cell Proliferation
  • Cell Transformation, Neoplastic/drug effects
  • Glioblastoma/drug therapy
  • Histone Deacetylases/chemistry
  • Humans
  • In Vitro Techniques
  • Male
  • Mice
  • Mice, Nude
  • Neoplastic Stem Cells/drug effects
  • Phenotype
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Cite this

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. / Marampon, Francesco; Leoni, Flavio; Mancini, Andrea; Pietrantoni, Ilaria; Codenotti, Silvia; Letizia, Ferella; Megiorni, Francesca; Porro, Giuliana; Galbiati, Elisabetta; Pozzi, Pietro; Mascagni, Paolo; Budillon, Alfredo; Maggio, Roberto; Tombolini, Vincenzo; Fanzani, Alessandro; Gravina, Giovanni Luca; Festuccia, Claudio.

In: Journal of Cancer Research and Clinical Oncology, Vol. 145, No. 2, 02.2019, p. 393-409.

Research output: Contribution to journalArticle

Marampon, F, Leoni, F, Mancini, A, Pietrantoni, I, Codenotti, S, Letizia, F, Megiorni, F, Porro, G, Galbiati, E, Pozzi, P, Mascagni, P, Budillon, A, Maggio, R, Tombolini, V, Fanzani, A, Gravina, GL & Festuccia, C 2019, 'Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma', Journal of Cancer Research and Clinical Oncology, vol. 145, no. 2, pp. 393-409. https://doi.org/10.1007/s00432-018-2800-8
Marampon, Francesco ; Leoni, Flavio ; Mancini, Andrea ; Pietrantoni, Ilaria ; Codenotti, Silvia ; Letizia, Ferella ; Megiorni, Francesca ; Porro, Giuliana ; Galbiati, Elisabetta ; Pozzi, Pietro ; Mascagni, Paolo ; Budillon, Alfredo ; Maggio, Roberto ; Tombolini, Vincenzo ; Fanzani, Alessandro ; Gravina, Giovanni Luca ; Festuccia, Claudio. / Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. In: Journal of Cancer Research and Clinical Oncology. 2019 ; Vol. 145, No. 2. pp. 393-409.
@article{a0ed8342bdde4879822592f71f128327,
title = "Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma",
abstract = "PURPOSE: Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential.METHODS: A set of GBM- and patient-derived GBM stem-cell lines was used and the ITF2357 effects on GBM oncophenotype were investigated in in vitro and in vivo xenograft models.RESULTS: ITF2357 inhibited HDAC activity and affected GBM cellular fate in a dose-dependent manner by inducing G1/S growth arrest (1-2.5 µM) or caspase-mediated cell death (≥ 2.5 µM). Chronic treatment with low doses (≤ 1 µM) induced autophagy-mediated cell death, neuronal-like phenotype, and the expression of differentiation markers, such as glial fibrillar actin protein (GFAP) and neuron-specific class III beta-tubulin (Tuj-1); this reduces neurosphere formation from patient-derived GBM stem cells. Autophagy inhibition counteracted the ITF2357-induced expression of differentiation markers in p53-expressing GBM cells. Finally, in in vivo experiments, ITF2357 efficiently passed the blood-brain barrier, so rapidly reaching high concentration in the brain tissues, and significantly affected U87MG and U251MG growth in orthotopic xenotransplanted mice.CONCLUSIONS: The present findings provide evidence of the key role played by HDACs in sustaining transformed and stem phenotype of GBM and strongly suggest that ITF2357 may have a clinical potential for the HDACi-based therapeutic strategies against GBM.",
keywords = "Animals, Apoptosis, Carbamates/pharmacology, Cell Movement, Cell Proliferation, Cell Transformation, Neoplastic/drug effects, Glioblastoma/drug therapy, Histone Deacetylases/chemistry, Humans, In Vitro Techniques, Male, Mice, Mice, Nude, Neoplastic Stem Cells/drug effects, Phenotype, Tumor Cells, Cultured, Xenograft Model Antitumor Assays",
author = "Francesco Marampon and Flavio Leoni and Andrea Mancini and Ilaria Pietrantoni and Silvia Codenotti and Ferella Letizia and Francesca Megiorni and Giuliana Porro and Elisabetta Galbiati and Pietro Pozzi and Paolo Mascagni and Alfredo Budillon and Roberto Maggio and Vincenzo Tombolini and Alessandro Fanzani and Gravina, {Giovanni Luca} and Claudio Festuccia",
year = "2019",
month = "2",
doi = "10.1007/s00432-018-2800-8",
language = "English",
volume = "145",
pages = "393--409",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

AU - Marampon, Francesco

AU - Leoni, Flavio

AU - Mancini, Andrea

AU - Pietrantoni, Ilaria

AU - Codenotti, Silvia

AU - Letizia, Ferella

AU - Megiorni, Francesca

AU - Porro, Giuliana

AU - Galbiati, Elisabetta

AU - Pozzi, Pietro

AU - Mascagni, Paolo

AU - Budillon, Alfredo

AU - Maggio, Roberto

AU - Tombolini, Vincenzo

AU - Fanzani, Alessandro

AU - Gravina, Giovanni Luca

AU - Festuccia, Claudio

PY - 2019/2

Y1 - 2019/2

N2 - PURPOSE: Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential.METHODS: A set of GBM- and patient-derived GBM stem-cell lines was used and the ITF2357 effects on GBM oncophenotype were investigated in in vitro and in vivo xenograft models.RESULTS: ITF2357 inhibited HDAC activity and affected GBM cellular fate in a dose-dependent manner by inducing G1/S growth arrest (1-2.5 µM) or caspase-mediated cell death (≥ 2.5 µM). Chronic treatment with low doses (≤ 1 µM) induced autophagy-mediated cell death, neuronal-like phenotype, and the expression of differentiation markers, such as glial fibrillar actin protein (GFAP) and neuron-specific class III beta-tubulin (Tuj-1); this reduces neurosphere formation from patient-derived GBM stem cells. Autophagy inhibition counteracted the ITF2357-induced expression of differentiation markers in p53-expressing GBM cells. Finally, in in vivo experiments, ITF2357 efficiently passed the blood-brain barrier, so rapidly reaching high concentration in the brain tissues, and significantly affected U87MG and U251MG growth in orthotopic xenotransplanted mice.CONCLUSIONS: The present findings provide evidence of the key role played by HDACs in sustaining transformed and stem phenotype of GBM and strongly suggest that ITF2357 may have a clinical potential for the HDACi-based therapeutic strategies against GBM.

AB - PURPOSE: Aberrant expression and activity of histone deacetylases (HDACs) sustain glioblastoma (GBM) onset and progression, and, therefore, HDAC inhibitors (HDACi) represent a promising class of anti-tumor agents. Here, we analyzed the effects of ITF2357 (givinostat), a pan-HDACi, in GBM models for its anti-neoplastic potential.METHODS: A set of GBM- and patient-derived GBM stem-cell lines was used and the ITF2357 effects on GBM oncophenotype were investigated in in vitro and in vivo xenograft models.RESULTS: ITF2357 inhibited HDAC activity and affected GBM cellular fate in a dose-dependent manner by inducing G1/S growth arrest (1-2.5 µM) or caspase-mediated cell death (≥ 2.5 µM). Chronic treatment with low doses (≤ 1 µM) induced autophagy-mediated cell death, neuronal-like phenotype, and the expression of differentiation markers, such as glial fibrillar actin protein (GFAP) and neuron-specific class III beta-tubulin (Tuj-1); this reduces neurosphere formation from patient-derived GBM stem cells. Autophagy inhibition counteracted the ITF2357-induced expression of differentiation markers in p53-expressing GBM cells. Finally, in in vivo experiments, ITF2357 efficiently passed the blood-brain barrier, so rapidly reaching high concentration in the brain tissues, and significantly affected U87MG and U251MG growth in orthotopic xenotransplanted mice.CONCLUSIONS: The present findings provide evidence of the key role played by HDACs in sustaining transformed and stem phenotype of GBM and strongly suggest that ITF2357 may have a clinical potential for the HDACi-based therapeutic strategies against GBM.

KW - Animals

KW - Apoptosis

KW - Carbamates/pharmacology

KW - Cell Movement

KW - Cell Proliferation

KW - Cell Transformation, Neoplastic/drug effects

KW - Glioblastoma/drug therapy

KW - Histone Deacetylases/chemistry

KW - Humans

KW - In Vitro Techniques

KW - Male

KW - Mice

KW - Mice, Nude

KW - Neoplastic Stem Cells/drug effects

KW - Phenotype

KW - Tumor Cells, Cultured

KW - Xenograft Model Antitumor Assays

U2 - 10.1007/s00432-018-2800-8

DO - 10.1007/s00432-018-2800-8

M3 - Article

VL - 145

SP - 393

EP - 409

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -